U.S. markets closed

Franklin Growth Series Class A (FKGRX)

Nasdaq - Nasdaq Delayed Price. Currency in USD
Add to watchlist
144.24+1.17 (+0.82%)
At close: 8:01PM EDT
Full screen
Previous Close143.07
YTD Return5.64%
Expense Ratio (net)0.82%
CategoryLarge Growth
Last Cap Gain0.00
Morningstar Rating★★★★★
Morningstar Risk RatingBelow Average
Sustainability Rating
Net Assets20.44B
Beta (5Y Monthly)1.00
Yield0.12%
5y Average ReturnN/A
Holdings Turnover9.01%
Last Dividend0.18
Average for CategoryN/A
Inception DateApr 01, 1948
  • Media Advisory - Eastern Ontario Regional Network (EORN) to make an announcement related to cellular connectivity
    CNW Group

    Media Advisory - Eastern Ontario Regional Network (EORN) to make an announcement related to cellular connectivity

    PETERBOROUGH COUNTY, ON, March 17, 2021 /CNW/ - Members of the accredited media are invited to join the Eastern Ontario Regional Network (EORN) for an announcement about cellular connectivity. Other participants include: The Honourable Maryam Monsef, Canada's Minister for Women and Gender Equality and Rural Economic Development; The Honourable Laurie Scott, Ontario's Minister of Infrastructure; Warden J.

  • Tetra Bio-Pharma Announces Closing of Bought Deal Offering
    CNW Group

    Tetra Bio-Pharma Announces Closing of Bought Deal Offering

    /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/OTTAWA, ON, March 2, 2021 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development, is pleased to announce it has closed its previously announced bought-deal public offering of units (the "Units") of the Company.

  • Tetra Bio-Pharma To Monetize Its Dronabinol And Botanical Product Portfolios
    ACCESSWIRE

    Tetra Bio-Pharma To Monetize Its Dronabinol And Botanical Product Portfolios

    Company signs LOI for Nordics and GermanyOTTAWA, ON / ACCESSWIRE / February 25, 2021 /Tetra Bio-Pharma Inc. ("Tetra" or the "Company")(TSX:TBP)(OTCQB:TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development announced the signing of a Letter of Intent with DanCann Pharma A/S (SS: DANCAN) for the exclusive distribution of Reduvo™ Adversa® and QIXLEEF™ in Denmark, Norway, Sweden, Finland, and Germany.